Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
HZNP was delisted on the 5th of October, 2023.
529 hedge funds and large institutions have $13B invested in Horizon Therapeutics Public Limited Company Ordinary Shares in 2022 Q3 according to their latest regulatory filings, with 61 funds opening new positions, 190 increasing their positions, 216 reducing their positions, and 138 closing their positions.
119% more call options, than puts
Call options by funds: $90.9M | Put options by funds: $41.4M
12% less repeat investments, than reductions
Existing positions increased: 190 | Existing positions reduced: 216
14% less funds holding
Funds holding: 614 → 529 (-85)
21% less capital invested
Capital invested by funds: $16.5B → $13B (-$3.49B)
46% less funds holding in top 10
Funds holding in top 10: 26 → 14 (-12)
56% less first-time investments, than exits
New positions opened: 61 | Existing positions closed: 138
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Barclays
London,
United Kingdom
|
+$249M |
| 2 |
Marshall Wace
London,
United Kingdom
|
+$164M |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$159M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
+$146M |
| 5 |
WP
Woodline Partners
San Francisco,
California
|
+$146M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$726M |
| 2 |
O
OrbiMed
New York
|
-$168M |
| 3 |
Allianz Asset Management
Munich,
Germany
|
-$140M |
| 4 |
Fidelity International
Hamilton,
Bermuda
|
-$127M |
| 5 |
Janus Henderson Group
London,
|
-$97.8M |
HZNP Hedge Fund Activity: Q3 2022 in Review
529 of the 5,828 institutional investors tracked by Wall St. Rank reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) for Q3 2022, worth a combined $13B — down 21% from $16.5B a quarter earlier.
Sellers outnumbered buyers: 138 funds closed out of HZNP and 61 opened new positions — a net loss of 77 holders — while 216 trimmed existing stakes and 190 added.
The largest buyer was Barclays, adding an estimated $249M. The largest seller was Fidelity Investments, cutting an estimated $726M.
- 529 institutional investors held Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) as of Q3 2022, down from 614 in Q2 2022.
- Funds reported $13B of Horizon Therapeutics Public Limited Company Ordinary Shares stock for Q3 2022, down 21% quarter-over-quarter.
- 61 funds opened new Horizon Therapeutics Public Limited Company Ordinary Shares positions in Q3 2022 and 138 closed out, a net change of -77 holders.
- The largest Horizon Therapeutics Public Limited Company Ordinary Shares buyer in Q3 2022 was Barclays, an estimated $249M added.
- The largest Horizon Therapeutics Public Limited Company Ordinary Shares seller in Q3 2022 was Fidelity Investments, an estimated $726M sold.
Based on aggregated 13F filings for Q3 2022.